Cognition Therapeutics, Inc. CGTX
Set alert
At close · Nov 2
After hours · Nov 2, 7:34 PM ET
- YTD
- -47.44%
- 1 year
- -60.36%
- Open
- 0.699
- Prev close
- 0.6982
- Mkt cap
- 67.48M
- Vol
- 346.58K
- Avg vol
- 516.99K
- EPS
- -0.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.699
- High
- 0.7399
- Forward P/E
- -0.80
- Beta
- 1.33
- Short ratio
- 1.07
- Inst. own
- 24.53%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.47888
- 200-d avg
- 1.23
- 1y target
- 6.50
News
15 hours ago globenewswire.com
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
-- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product…
-
1 week ago benzinga.com
Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints
The planned registrational study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine…
1 week ago globenewswire.com
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat…
-
2 weeks ago benzinga.com
Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine
The patent has a natural expiration of 2045. Upon zervimesine’s approval by the U.S. Food and Drug Administration (FDA), the patent may be eligible for an extension of up to five additional years.The…
2 weeks ago globenewswire.com
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
- An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
-
1 month ago benzinga.com
Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"),
1 month ago globenewswire.com
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
1 month ago globenewswire.com
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
2 months ago zacks.com
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
Cognition Therapeutics, Inc. (CGTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.11 per share a year ago.
-
2 months ago benzinga.com
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses…
2 months ago globenewswire.com
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the…
3 months ago globenewswire.com
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
PURCHASE, N. Y. , July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
4 months ago seekingalpha.com
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no…
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…
-
4 months ago benzinga.com
FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it…
4 months ago globenewswire.com
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -
-
4 months ago benzinga.com
Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has…
4 months ago globenewswire.com
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative…
5 months ago globenewswire.com
Cognition Therapeutics Participating in Upcoming Investor Conferences
PURCHASE, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
5 months ago globenewswire.com
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a…
-
5 months ago benzinga.com
Cognition Therapeutics Announces Second Philanthropic Donation From A Participant In The Ongoing Expanded Access Program For People With Dementia With Lewy Bodies
The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach,…
5 months ago globenewswire.com
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative…
5 months ago globenewswire.com
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition…
6 months ago defenseworld.net
Cognition Therapeutics (NASDAQ:CGTX) CEO Lisa Ricciardi Acquires 9,175 Shares of Stock
Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was bought at an…
6 months ago defenseworld.net
Cognition Therapeutics (NASDAQ:CGTX) CFO John Brendan Doyle Buys 10,000 Shares
Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CFO John Brendan Doyle acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The shares were…
6 months ago defenseworld.net
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics (NASDAQ: CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage…
-
6 months ago benzinga.com
Cognition Therapeutics To Update On Progress Of Its Development Programs For Alzheimer's Disease And Dementia With Lewy Bodies At 25th Annual Needham Virtual Healthcare Conference
Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to…
6 months ago globenewswire.com
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
7 months ago benzinga.com
Cognition Therapeutics Q4 EPS $(0.01) Beats $(0.05) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.05) by 80 percent. This is a 94.12 percent increase over losses of…
7 months ago benzinga.com
Earnings Scheduled For March 26, 2026
Earnings Scheduled For March 26, 2026
-
7 months ago benzinga.com
Cognition Therapeutics Presents Analysis From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2…
-
9 months ago benzinga.com
Cognition Therapeutics Extends Duration Of Expanded Access Program For Dementia With Lewy Bodies
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the…
-
9 months ago benzinga.com
Cognition Therapeutics Meets With FDA to Plan Mid-Stage Trial for Lewy Body Dementia Drug
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food…
-
10 months ago benzinga.com
Cognition Therapeutics Study On Phase 2 Trial Of Zervimesine In Patients With Mild-to-Moderate Dementia With Lewy Bodies Meets Primary Endpoint Of Safety, Tolerability
Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, "Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate Dementia with Lewy Bodies (DLB)"…
-
10 months ago benzinga.com
Cognition Therapeutics Files Prospectus To Offer Up To $300M In Securities
Common StockPreferred StockDebt SecuritiesWarrantsUnitsSubscription RightsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or…
-
11 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
-
11 months ago benzinga.com
Cognition Therapeutics Reaches Full Patients Enrollment For Zervimesine In Dementia Trial
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded access…
-
11 months ago benzinga.com
Cognition Therapeutics Presented Plans For Registrational Program For Zervimesine In Mild-To-Moderate Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented plans for a registrational program…
-
11 months ago benzinga.com
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3
B. Riley Securities analyst William Woods reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and raises the price target from $2 to $3.
-
11 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.
-
11 months ago benzinga.com
Cognition Therapeutics Reaches Target Enrollment Of 540 Patients In Phase 2 START Trial To Evaluate Zervimesine To Treat Early Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target…
-
12 months ago benzinga.com
Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 76 percent increase over losses of…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
Reported Earlier: Cognition Therapeutics Reports Zervimesine (CT1812) Results In Phase 2 SHIMMER DLB, SHINE Alzheimer's & MAGNIFY Dry AMD Studies; Moving Toward Phase 3 Trials
https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_ex99-1.htm
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
Reported Earlier, Cognition Therapeutics Secures $30M From Registered Direct Offering Made To Two Fundamental Institutional Investors
- The offering was made to two new fundamental institutional investors -- The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session